A Phase III Randomized Study of Oral Sapacitabine in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia
The goal of this clinical research study is to compare the ability of decitabine given alone versus the combination of sapacitabine and decitabine to control AML. The safety of the drug combination will also be studied.
Treatment Location: N/A
The primary objective is to compare the overall survival between Arm A and Arm C the secondary objectives are to assess the response rate of CR, CRp, PR, HI, SD and their corresponding durations, transfusion requirements, number of hospitalized days, 1-year survival and safety.
IRB Review and Approval Date: 02/07/2011
Recruitment Status: Closed
Projected Accrual: N/A
Information and next steps
For general questions about clinical trials: